期刊
HAEMATOLOGICA
卷 106, 期 6, 页码 1608-1615出版社
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2018.212571
关键词
-
类别
资金
- Leukemia and Lymphoma Society SCOR grant [700411, NCI-7 P50 CA14015802, NCI-P30 CA016058]
- D Warren Brown Foundation
Mutations in the IGH variable region are associated with a favorable prognosis in patients with chronic lymphocytic leukemia, while cytogenetic complexity and translocations are linked to an unfavorable prognosis. The presence of a translocation in IGHV-mutated patients appears to negate the improved prognosis of mutated IGHV.
Mutations of the IGH variable region in patients with chronic lymphocytic leukemia are associated with a favorable prognosis, whereas cytogenetic complexity (>= 3 unrelated aberrations) and translocations have been associated with an unfavorable prognosis. While mutational status of IGHV is stable, cytogenetic aberrations frequently evolve. However, the relationships of these features as prognosticators at diagnosis are unknown. We examined the CpG-stimulated metaphase cytogenetic features detected within 1 year of diagnosis of chronic lymphocytic leukemia and correlated these features with outcome and other clinical features including IGHV mutational status. Of 329 untreated patients, 53 (16.1%) had a complex karyotype, and 85 (25.8%) had a translocation. The median time to first treatment (TFT) was 47 months. In univariable analyses, significant risk factors for shorter TFT (P<0.05) were Rai stage 3-4, b 2-microglobulin >3.5 mg/L, log-transformed white blood cell count, unmutated IGHV, a complex karyotype, a translocation, and trisomy 8, del(11q) or del(17p) detected by fluorescence in situ hybridization. In multivariable analysis, there was a significant effect modification of IGHV status on the relationship between translocation and TFT (P=0.002). In IGHV-mutated patients, those with a translocation had an over 3.5 times higher risk of starting treatment than those without a translocation (P<0.001); however, among IGHV-unmutated patients, a translocation did not significantly increase the risk of starting treatment (hazard ratio 1.00, P=0.99). The effect of Rai stage 3-4, log-transformed white blood cell count and complex karyotype remained statistically significant, whereas that of del(17p) did not (P=0.51). In summary, the presence of a translocation in IGHV-mutated patients appeared to negate the improved prognosis of mutated IGHV, but the presence of a translocation did not have an effect on TFT in high-risk IGHV-unmutated patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据